2.72
-0.29(-9.63%)
Currency In USD
| Previous Close | 3.01 |
| Open | 3.05 |
| Day High | 3.05 |
| Day Low | 2.67 |
| 52-Week High | 7.95 |
| 52-Week Low | 1.98 |
| Volume | 290,743 |
| Average Volume | 290,050 |
| Market Cap | 16.02M |
| PE | -2.34 |
| EPS | -1.16 |
| Moving Average 50 Days | 3.59 |
| Moving Average 200 Days | 3.6 |
| Change | -0.29 |
If you invested $1000 in Vivos Therapeutics, Inc. (VVOS) since IPO date, it would be worth $12.1 as of October 27, 2025 at a share price of $2.72. Whereas If you bought $1000 worth of Vivos Therapeutics, Inc. (VVOS) shares 3 years ago, it would be worth $147.03 as of October 27, 2025 at a share price of $2.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep ApneaLITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
GlobeNewswire Inc.
Sep 17, 2025 12:30 PM GMT
The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSALITTLETON, Col
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
GlobeNewswire Inc.
Aug 19, 2025 12:30 PM GMT
Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ETLITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing i